Doseology Sciences (XCNQ:MOOD) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Doseology Sciences Debt-to-Equity?

Doseology Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Doseology Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was C$0.00 Mil. Doseology Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$1.17 Mil. Doseology Sciences's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Doseology Sciences's Debt-to-Equity or its related term are showing as below:

XCNQ:MOOD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.2 Max: 0.3
Current: 0.04

During the past 4 years, the highest Debt-to-Equity Ratio of Doseology Sciences was 0.30. The lowest was 0.03. And the median was 0.20.

XCNQ:MOOD's Debt-to-Equity is ranked better than
76.5% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs XCNQ:MOOD: 0.04

Doseology Sciences Debt-to-Equity Historical Data

The historical data trend for Doseology Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Doseology Sciences Debt-to-Equity Chart

Doseology Sciences Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

0.27

0.25

0.04

Doseology Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										0.20	0.20	0.04	0.03	-

Competitive Comparison of Doseology Sciences's Debt-to-Equity

For the Biotechnology subindustry, Doseology Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Doseology Sciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Doseology Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Doseology Sciences's Debt-to-Equity falls into.

Doseology Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Doseology Sciences's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.043	+	0.008)	/	1.3
	=	0.04

Doseology Sciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	1.171
	=	0.00

Doseology Sciences (XCNQ:MOOD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Doseology Sciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Doseology Sciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Doseology Sciences (XCNQ:MOOD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Doseology Sciences Inc (XCNQ:MOOD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

DOSEF:USA

Address

116 - 5100 Anderson Way, Unit 197, Vernon, BC, CAN, V1T 0C4

Website

https://www.doseology.com

Doseology Sciences Inc is a diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on the psychedelic and non-psychedelic compounds, also sale of its branded functional mushroom products. Doseology offers cutting-edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health.

Doseology Sciences (XCNQ:MOOD) Headlines

No Headlines